EpimAb Biotherapeutics (Group)

https://www.epimab.com

EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company based in Shanghai with a proprietary unique and efficient technology called FIT-Ig (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties. With this platform EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients. EpimAb is also committed to diversifying its pipeline through selective licensing of its platform to partners worldwide. *

	Start	2016-10-11 existent
	Today	EpimAb Biotherapeutics Inc. (CN)
	Industry	bispecific antibody
	Industry 2	Fabs-In-Tandem Immunoglobulin (FIT-Ig™) platform
	Person	Wu, Chengbin (EpimAb Biotherapeutics 201610 CEO + Founder)
	Person 2	Lensky, Stephan (EpimAb Biotherapeutics 201610 COO/CBO)

	Region	Shanghai
	Country	China
	City	201203 Shanghai
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)